Educational use only. Check doses against the product monograph and local protocols.

dobutamine

in review 2 min read Updated 2026-10-30
start
2–2.5 mcg/kg/min
no bolus · titrate by 2.5 to perfusion
usual range
2–10 mcg/kg/min
up to 20 (ESC HF)
HR
↑
CO
↑↑
SVR
↓
dobutamine

β1-predominant inodilator: raises contractility and cardiac output and lowers SVR and PCWP (filling pressures fall as the LV empties better). Used for low-output states with adequate BP: cardiogenic shock (with norepinephrine if hypotensive) and septic cardiomyopathy with persistent hypoperfusion. Fast on, fast off, so it’s easy to titrate. Hypotension and tachyarrhythmia are the limits.

mechanism

β1 (+++) and β2 (++) agonist with weak α1 → ↑ inotropy and chronotropy, mild vasodilation (inodilator).


dosing

settingdose
start2–2.5 mcg/kg/min, no bolus
titrateby 2.5 mcg/kg/min to perfusion (lactate, urine output, mentation, ScvO₂/cardiac output)
usual range2–10 mcg/kg/min (up to 20 in ESC HF)
onset / offset1–10 min / half-life ~2 min
  • no renal or hepatic adjustment
  • lowest effective dose for the shortest time (ACC 2025)

key points

  • inotrope, not pressor: in a hypotensive patient it can drop BP further → pair with norepinephrine. In septic cardiomyopathy, MAP often rises as cardiac output improves
  • septic shock: add to norepinephrine (or switch to epinephrine alone) when LV dysfunction and hypoperfusion persist despite adequate MAP and volume (SSC 2026, conditional, very low certainty) → septic shock
  • dobutamine vs milrinone: no outcome difference (DOREMI (2021)). Dobutamine is quicker to stop, better with AKI and less hypotensive; milrinone works better under β-blockade and in RV failure with high PVR → milrinone
  • chronic β-blocker: blunted response. Higher doses or milrinone/levosimendan instead (ESC)
  • dynamic LVOT obstruction (hyperdynamic underfilled LV, HCM, after apical MI): dobutamine worsens it → stop and give volume ± pure vasoconstrictor
  • inotropes don’t improve survival in HF; they bridge to recovery, revascularisation, mechanical support or advanced therapies → cardiogenic shock

adverse effects

  • tachyarrhythmia: sinus tachycardia, AF with fast ventricular rate, VT
  • hypotension (β2 vasodilation), especially if under-filled
  • myocardial ischaemia (↑ O₂ demand)
  • tolerance with prolonged infusion

evidence

  • DOREMI (2021) — milrinone vs dobutamine in cardiogenic shock (n=192): no difference in composite in-hospital death, arrest, transplant/MCS, MI, stroke or RRT

Prepared 2026-10-30. Not yet verified — check every number against the sources.

Key references

+1 more source

Suggest a correction dobutamine